1. Home
  2. ENSC vs LAES Comparison

ENSC vs LAES Comparison

Compare ENSC & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • LAES
  • Stock Information
  • Founded
  • ENSC 2003
  • LAES 2022
  • Country
  • ENSC United States
  • LAES Switzerland
  • Employees
  • ENSC N/A
  • LAES N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • LAES Semiconductors
  • Sector
  • ENSC Health Care
  • LAES Technology
  • Exchange
  • ENSC Nasdaq
  • LAES Nasdaq
  • Market Cap
  • ENSC 9.5M
  • LAES 10.7M
  • IPO Year
  • ENSC N/A
  • LAES N/A
  • Fundamental
  • Price
  • ENSC $6.07
  • LAES $2.33
  • Analyst Decision
  • ENSC
  • LAES Strong Buy
  • Analyst Count
  • ENSC 0
  • LAES 1
  • Target Price
  • ENSC N/A
  • LAES $1.75
  • AVG Volume (30 Days)
  • ENSC 154.9K
  • LAES 49.6M
  • Earning Date
  • ENSC 11-12-2024
  • LAES 09-25-2024
  • Dividend Yield
  • ENSC N/A
  • LAES N/A
  • EPS Growth
  • ENSC N/A
  • LAES N/A
  • EPS
  • ENSC N/A
  • LAES N/A
  • Revenue
  • ENSC $4,421,404.00
  • LAES $20,135,000.00
  • Revenue This Year
  • ENSC N/A
  • LAES N/A
  • Revenue Next Year
  • ENSC N/A
  • LAES N/A
  • P/E Ratio
  • ENSC N/A
  • LAES N/A
  • Revenue Growth
  • ENSC 40.41
  • LAES N/A
  • 52 Week Low
  • ENSC $2.12
  • LAES $0.29
  • 52 Week High
  • ENSC $30.90
  • LAES $3.95
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 42.77
  • LAES 83.63
  • Support Level
  • ENSC $5.34
  • LAES $0.35
  • Resistance Level
  • ENSC $8.27
  • LAES $3.46
  • Average True Range (ATR)
  • ENSC 1.06
  • LAES 0.30
  • MACD
  • ENSC -0.24
  • LAES 0.27
  • Stochastic Oscillator
  • ENSC 18.43
  • LAES 76.85

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

Share on Social Networks: